Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
LIN$524.00+15.84(+3.12%)Linde Reports Third-Quarter 2026 Results[5:30:00 AM ET]HLRTF$0.09+0.00(+4.00%)Hillcrest Energy Technologies to Present at Market Bridge Live in London[5:30:00 AM ET]TTTMF$0.14+0.00(+2.51%)Total Metals Provides Exploration Drilling Update at its High Lake High-Grade Gold Project, Northwestern Ontario[5:15:00 AM ET]OCS$7.98+0.15(+1.92%)Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit[5:10:21 AM ET]PHG$27.16+0.13(+0.48%)Philips launches UniGuide 3D Live Guidance, bringing CT planning into live procedures and extending the capabilities of its Azurion image-guided therapy platform[5:00:00 AM ET]TAL$9.64-0.42(-4.17%)TAL Education Group Announces Unaudited Financial Results for the Second Fiscal Quarter Ended August 31, 2026, Declares Cash Dividend and Issues Notice of Annual General Meeting TAL Education Group (NYSE: TAL) ("TAL" or the "Company"), a smart learning solutions provider in China, today announced its unaudited financial...[5:00:00 AM ET]AOS$60.86-1.20(-1.93%)AOS to Showcase Breakthrough Power Solutions for AI Core Power, AI Data Center and Industrial Designs at electronica 2026[5:00:00 AM ET]CSGP$27.70+0.16(+0.58%)CoStar Data Shows London Demand for 4 Star Offices Topping 40% in the City Core despite Top-Quality Space Shortage[5:00:00 AM ET]FCSMF$0.27+0.01(+3.85%)Focus Graphite Engages BTV for National Television and U.S. Broadcast Investor Awareness Campaign[5:00:00 AM ET]POR$44.50+0.23(+0.52%)Portland General Electric Announces Third Quarter 2026 Results[5:00:00 AM ET]WTKWY$93.60-2.12(-2.21%)Share Buyback Transaction Details October 22 – October 28, 2026[5:00:00 AM ET]TRRFF$0.100.00(0.00%)Trifecta Gold Announces Drill Results from Rye Project, Yukon[5:00:00 AM ET]VG$14.36+0.01(+0.07%)Bdeo Takes Quality on Demand Live, Powered by Vonage, to Transform Insurance Claims Globally[5:00:00 AM ET]

PRME · NASDAQ

Prime Medicine, Inc.

$5.28 -0.09 (-1.68%)

Company overview

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$958M
Employees
214
Headquarters
Cambridge, MA
Website
primemedicine.com
CEO
Allan Reine
Listed
October 20, 2022
P/E
-4.17
Dividend yield
6.80%

Company financials

Revenue
$4M
Gross profit
-$43.7M
Operating income
-$207M
EBITDA
-$196M
Net income
-$198M
EPS
-$1.27
Total assets
$295M
Total debt
$115M
Gross margin
-1,082.70%
Net margin
-4,917.55%
Earnings yield
-24.00%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

2.563.294.024.765.49
PRME 1D NASDAQ O4.24H5.38L4.11C5.37+1.02 (+23.45%)Vol4.78M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
PRMEPrime Medicine, Inc. Stock news Prime Medicine, Inc. (PRME) Surges 23.2%: Is This an Indication of Further Gains? Zacks Investment Research
PRMEPrime Medicine, Inc. Press release Prime Drink Group Announces Subscription Receipt Financing and Closing of Second Tranche of Private Placement of Units Business Wire
PRMEPrime Medicine, Inc. Stock news Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why Zacks Investment Research
PRMEPrime Medicine, Inc. Stock news Leading Indicators For The October Breakout Cycle Seeking Alpha
PRMEPrime Medicine, Inc. Stock news Apogee Enterprises Posts Upbeat Q2 Earnings, Joins Constellation Energy, Freshworks And Other Big Stocks Moving Higher On Tuesday Benzinga
PRMEPrime Medicine, Inc. Press release Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease GlobeNewsWire
PRMEPrime Medicine, Inc. Stock news Prime Medicine Gets FDA Green Light for Gene Editing Study Benzinga
INLF Stock news Why INLIF Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket Benzinga
PRMEPrime Medicine, Inc. Stock news Costco Wholesale, Scholastic and 3 Stocks to Watch Heading Into Friday Benzinga
PRMEPrime Medicine, Inc. Press release Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency GlobeNewswire
PRMEPrime Medicine, Inc. Stock news Prime Medicine, Inc. (PRME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
PRMEPrime Medicine, Inc. Stock news Prime Drink Group Provides Bi-Weekly MCTO Status Report GlobeNewsWire
PRMEPrime Medicine, Inc. Press release Prime Medicine to Participate in Upcoming Investor Conferences GlobeNewswire
PRMEPrime Medicine, Inc. Stock news Prime Medicine: Soon In The Clinic Seeking Alpha
PRMEPrime Medicine, Inc. Stock news Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates Zacks Investment Research
PRMEPrime Medicine, Inc. Stock news Prime Medicine, Inc. $PRME Shares Sold by Amova Asset Management Americas Inc. Defense World
PRMEPrime Medicine, Inc. Stock news Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investable Seeking Alpha
PRMEPrime Medicine, Inc. Stock news Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case Benzinga
PRMEPrime Medicine, Inc. Stock news Penguin Solutions, Beazer Homes, Alibaba And Other Big Stocks Moving Higher On Wednesday Benzinga
PRMEPrime Medicine, Inc. Press release Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics GlobeNewsWire
See more
FAQ

Questions about Prime Medicine, Inc.

What does Prime Medicine, Inc. do?
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
What is PRME's market cap?
Prime Medicine, Inc. (PRME) is a listed stock with a live quote. The latest market cap on this page is $958M.
Where is Prime Medicine, Inc. headquartered?
Prime Medicine, Inc. is headquartered in Cambridge, MA.
How do I get PRME news from the API?
Call GET /v1/news?tickers=PRME. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does PRME news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for PRME, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the PRME price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs